Ignite Creation Date:
2025-12-25 @ 4:12 AM
Ignite Modification Date:
2026-02-24 @ 12:42 PM
Study NCT ID:
NCT00114920
Status:
COMPLETED
Last Update Posted:
2007-02-19
First Post:
2005-06-20
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Twelve Week Safety and Efficacy Study With a Topical Gel to Treat Common Warts in Adults
Sponsor:
Graceway Pharmaceuticals, LLC
Organization:
Study Overview
Official Title:
A Three-Stage, Modified-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel for the Treatment of Common Warts in Adults
Status:
COMPLETED
Status Verified Date:
2006-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary purpose of this study is to evaluate the effectiveness in adults, of four different strengths of resiquimod gel applied to common wart(s) three times a week for twelve weeks.
A second purpose is to evaluate the safety of the drug.
A second purpose is to evaluate the safety of the drug.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
Is a FDA Regulated Drug?:
Is a FDA Regulated Device?:
Is an Unapproved Device?:
Is a PPSD?:
Is a US Export?:
Is an FDA AA801 Violation?: